Indications
Therapeutic Asset Ratings
6,308 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
etx101
Dravet Syndrome
Encoded Therapeutics
P1/2
CC
(47)
Etx-19477
Castration-Resistant Prostate Carcinoma
858 Therapeutics, Inc.
P1/2
CC
(47)
Etx-19477
Estrogen-Receptor Positive Breast Cancer
858 Therapeutics, Inc.
P1/2
CC
(47)
exg110
Fabry Disease
Guangzhou Jiayin Biotech Ltd
P1/2
CC
(47)
Favezelimab
Renal Cell Carcinoma
Merck Sharp & Dohme LLC
P1/2
CC
(47)
Fludarabine
Gastric Adenocarcinoma
Beijing Biotech
P1/2
CC
(47)
Fludarabine
Cortical Thymoma
Beijing Biotech
P1/2
CC
(47)
Fludarabine
Ovarian Serous Adenocarcinoma
TCR2 Therapeutics
P1/2
CC
(47)
Fludarabine
Peritoneal Carcinomatosis
M.D. Anderson Cancer Center
P1/2
CC
(47)
Fludeoxyglucose
Follicular Lymphoma
University of Washington
P1/2
CC
(47)
Fluvustat
Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
P1/2
CC
(47)
Fosciclopirox
Acute Myeloid Leukemia
CicloMed LLC
P1/2
CC
(47)
fwd1802
Estrogen-Receptor Positive Breast Cancer
Forward Pharmaceuticals Co., Ltd.
P1/2
CC
(47)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa
Non-Small Cell Squamous Lung Carcinoma
Hummingbird Bioscience
P1/2
CC
(47)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa
Cervical Squamous Cell Carcinoma
Hummingbird Bioscience
P1/2
CC
(47)
Gavo-Cel
Ovarian Serous Adenocarcinoma
TCR2 Therapeutics
P1/2
CC
(47)
gb261
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Genor Biopharma Co., Ltd.
P1/2
CC
(47)
gb3226
Acute Myeloid Leukemia
Galecto Biotech AB
P1/2
CC
(47)
gc101
Spinal Muscular Atrophy
GeneCradle Inc
P1/2
CC
(47)
gc101
Spinal Muscular Atrophy, Type III
GeneCradle Inc
P1/2
CC
(47)
gc301
Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset
GeneCradle Inc
P1/2
CC
(47)
Gedatolisib
Male Reproductive System Disorder
Celcuity Inc
P1/2
CC
(47)
Gedatolisib
Prostate Disorder
Celcuity Inc
P1/2
CC
(47)
gh509
Metabolic Dysfunction-Associated Steatohepatitis
1Globe Biomedical Co., Ltd.
P1/2
CC
(47)
gi-102
Ovarian Cancer
GI Innovation, Inc.
P1/2
CC
(47)
Showing 2351 to 2375 of 6,308 assets
Previous
Page 95 of 253
Next
